Literature DB >> 12970754

Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.

John A Copland1, Bruce A Luxon, Laila Ajani, Tapati Maity, Erica Campagnaro, Huiping Guo, Shauna N LeGrand, Pheroze Tamboli, Christopher G Wood.   

Abstract

Renal cell carcinoma (RCC) is a major health issue. Whereas localized disease can be cured surgically, there is no effective therapy for metastatic disease. The development of an effective therapy will require an understanding of the pathways that are important in RCC carcinogenesis and progression. Using genomic profiling of patient-matched tissue, we have identified aberrations in the transforming growth factor beta (TGFbeta) signaling pathway in RCC. We observed loss of type III TGFbeta receptor (TBR3) expression in all RCC samples. This suggests that TBR3 loss is an early event in RCC carcinogenesis and plays a sentinel role in the acquisition of a tumorigenic phenotype. We also observed subsequent loss of type II TGFbeta receptor (TBR2) expression in metastatic RCCs. We propose that loss of TBR3 is necessary for RCC carcinogenesis, and that loss of TBR2 leads to acquisition of a metastatic phenotype. To this end, we have identified a human renal cell carcinoma line (UMRC6) that is representative of localized, nonmetastatic RCC, reflecting a loss of TBR3, but not TBR2 expression. Another cell line, UMRC3, is highly metastatic, having lost TBR3 and TBR2 expression. We demonstrate functional loss of TGFbeta responsiveness in these cell lines as observed through phenotypic and transcriptional responsiveness to exogenous TGFbeta. Restoring TBR2 and TBR3 expression in UMRC3 cells attenuates cell proliferation, completely restores TGFbeta-mediated transcriptional responses, and completely blocks anchorage independent-growth: while restoration of TBR2 partially restores TGFbeta-mediated signaling. Based on these data, we propose that dysregulation in TGFbeta signaling, through stepwise loss in receptor expression, plays a prominent role in RCC carcinogenesis and progression. In addition, these studies unequivocably demonstrate a link between loss of TBR3 and a human disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12970754     DOI: 10.1038/sj.onc.1206835

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  A duplicated motif controls assembly of zona pellucida domain proteins.

Authors:  Luca Jovine; Huayu Qi; Zev Williams; Eveline S Litscher; Paul M Wassarman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 2.  Renal cell carcinoma deep sequencing: recent developments.

Authors:  Leslie J Farber; Kyle Furge; Bin Tean Teh
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 3.  Proteoglycan signaling co-receptors: roles in cell adhesion, migration and invasion.

Authors:  Karthikeyan Mythreye; Gerard C Blobe
Journal:  Cell Signal       Date:  2009-05-08       Impact factor: 4.315

4.  Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Authors:  S J Cooper; H Zou; S N Legrand; L A Marlow; C A von Roemeling; D C Radisky; K J Wu; N Hempel; V Margulis; H W Tun; G C Blobe; C G Wood; J A Copland
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

5.  Changes in expression of genes related to cell proliferation in human mesenchymal stem cells during in vitro culture in comparison with cancer cells.

Authors:  Rumi Sawada; Tomomi Ito; Toshie Tsuchiya
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

6.  Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas.

Authors:  Mahlon D Johnson; Aubie K Shaw; Mary J O'Connell; Fraser J Sim; Harold L Moses
Journal:  J Neurooncol       Date:  2010-09-19       Impact factor: 4.130

7.  Type III TGF-β receptor enhances colon cancer cell migration and anchorage-independent growth.

Authors:  Catherine E Gatza; Alisha Holtzhausen; Kellye C Kirkbride; Allyson Morton; Michael L Gatza; Michael B Datto; Gerard C Blobe
Journal:  Neoplasia       Date:  2011-08       Impact factor: 5.715

8.  Type III transforming growth factor-beta (TGF-beta) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-beta signaling pathway.

Authors:  Vitaly Margulis; Tapati Maity; Xiu-Ying Zhang; Simon J Cooper; John A Copland; Christopher G Wood
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

Review 9.  Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis, and treatment selection.

Authors:  Jon Jones; Allan J Pantuck
Journal:  Curr Urol Rep       Date:  2008-01       Impact factor: 3.092

10.  The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2.

Authors:  Hye Jin You; Tam How; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2009-03-26       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.